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Background: Radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) are treatment methods for
patients with early-stage hepatocellular carcinoma (HCC) who are not suitable for surgery. Although some reports
indicate that RFA is better than PEI, results from previous reviews and analyses are inconsistent. Therefore, this
meta-analysis was performed to more thoroughly evaluate the effects of these treatments in patients with HCC.
Methods: A literature search was conducted using the Excerpta Medica dataBASE, PubMed, the Cochrane Library,
the American Society of Clinical Oncology database, the China National Knowledge Infrastructure database, the
Wanfang database, the Chinese Biomedical Literature Database, and the Chongqing VIP database without language
limitations. The primary outcome evaluated was overall survival, and secondary outcomes included complete
response and local recurrence. Comparisons were made between Asian and European studies.
Results: Total pooled and subgroup analyses of Asian studies that included selection biases revealed that RFA is
superior to PEI with respect to overall survival (hazard ratio (HR), 0.54; 95% confidence interval (CI), 0.37 to 0.80; P < 0.01)
and complete response (relative risk (RR), 1.10; 95% CI 1.03 to 1.18; P < 0.01). However, no significant difference
was observed between RFA and PEI in the European studies. In Asian studies, RFA was associated with a lower
local recurrence rate than PEI at 1 year (RR, 0.44; 95% CI 0.20 to 0.95; P < 0.05) and 3 years (RR, 0.35; 95% CI 0.22 to
0.55; P < 0.01). However, local recurrence was significantly lower after only 3 years in European studies (RR, 0.50;
95% CI 0.32 to 0.78; P < 0.05).
Conclusions: RFA was only superior to PEI in Asian studies that included selection bias. Thus, there is insufficient
evidence to support the idea that RFA is superior to PEI for patients with cirrhotic HCC. Additional large-scale,
multicenter, randomized controlled trials that control for selection bias are needed to fully elucidate the optimal
treatment method for HCC.
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Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer and the third most frequent cause of cancer-
related deaths worldwide [1]. HCC is a global problem,
and its incidence is increasing in both the United
States and Europe [2-5]. Surgical resection and liver* Correspondence: zhengyinliao@vip.sina.com
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unless otherwise stated.transplantation are effective for the treatment of HCC
[6,7]. Nevertheless, the surgical options for HCC are
often limited due to concurrent hepatic cirrhosis, poor
liver function, or multiple lesions [6,8-10]. Unfortunately,
liver transplantation plays a very small role in the treat-
ment of HCC because of ethical problems and a shortage
of liver donors [11,12]. Thus, various nonsurgical treat-
ment methods have been developed, including trans-
catheter arterial chemoembolization, percutaneous ethanol
injection (PEI), radiofrequency ablation (RFA), and percu-
taneous acid injection.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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to clinical practice [8,13]. It is a simple, inexpensive, safe,
effective technique with a low complication rate and can
achieve complete necrosis of small HCC lesions [14-17].
Therefore, in 2001, the European Association for the
Study of the Liver recommended PEI as the standard
percutaneous treatment for early-stage, nonsurgical HCC
[6]. However, PEI has some limitations, including the need
for multiple treatment sessions and a prolonged treatment
time [6].
In 1999, RFA was first conducted for the treatment of
HCC in Japan [18]. Its advantages over PEI include ease
of performance, effectiveness similar to that of surgical
resection, high safety, and low invasiveness [19-22]. The
American Association for the Study of Liver Diseases
published guidelines in 2005 (updated in 2010) indicating
that RFA is the first-choice procedure for patients with
HCC, especially patients with tumors that are ≤3 cm in
diameter and comprise one to three nodules. However,
PEI still plays an important role in the local treatment
of early-stage HCC [6,23]. Despite the advantages of
RFA, complete ablation remains difficult to achieve in
some specific liver sites; RFA is also more expensive
than PEI [21,24].
To the best of our knowledge, four Asian randomized
controlled trials (RCTs) have indicated that RFA is super-
ior to PEI in terms of overall survival (OS), complete re-
sponse (CR), and local recurrence (LR) [25-28]. However,
these trials may have included selection bias, as trials per-
formed in Europe have shown no significant differences
between RFA and PEI with respect to OS [16,29-32]. The
most effective treatment strategy for patients with unre-
sectable HCC thus remains controversial. The present
meta-analysis was performed to compare the effects of
RFA and PEI for the treatment of HCC.
Methods
Search strategy
The following databases were searched for all published
and unpublished RCTs with no language restrictions:
Excerpta Medica dataBASE (EMBASE), PubMed, Cochrane
Central Register of Controlled Trials, Cochrane Method-
ology Register, Cochrane Database of Systematic Reviews,
Cochrane Library, American Society of Clinical Oncology
database (ASCO), China National Knowledge Infrastruc-
ture database (CNKI), Chinese Biomedical Literature
(CBM) Database, Wanfang database, and the Chongqing
VIP database (CQVIP). Combinations of the following
terms were used in the search: medical subject headings =
liver neoplasms, catheter ablation, ethanol, and injections
intraregional; free text terms = hepatocellular carcinoma,
liver cancer, liver tumor, radiofrequency ablation, RFA,
ethanol injection, alcohol injection, and PEI. We also per-
formed a supplementary literature search through GoogleScholar and some leading journals. The publication cutoff
date was 14 March 2014. Each search strategy was de-
termined after numerous pre-searches. The reference
lists of all included studies were examined for relevant
publications.
Eligibility criteria
All procedures were performed in compliance with the
Declaration of Helsinki. This study was also approved by
the Committee on the Ethics West China Hospital. The
inclusion criteria were as follows: (i) studies including
patients with unresectable lesions, Child-Pugh class A or
B liver function, and inclusion of both an RFA and PEI
group (in studies comparing two or more arms); (ii) RFA
as the intervention and PEI as the comparator; (iii) inclu-
sion of data related to OS (percentage of patients who
survived for a defined period of time after treatment),
and at least one of the following secondary outcomes:
LR (percentage of patients with newly detected liver tu-
mors in the posttreatment follow-up period), CR (lower
incidence of liver tumors posttreatment), and treatment-
related adverse events or complications; and (iv) RCT was
the study design.
The exclusion criteria were as follows: (i) phase 2 RCTs,
(ii) lesions >5 cm in diameter (ablation techniques alone
are less effective in larger tumors [33]), and (iii) history of
surgical treatment for HCC.
Assessment of study quality
We used the Cochrane Collaboration handbook to assess
the risk of bias in all included studies [34]. The quality
items assessed included sequence generation, allocation
concealment, baseline imbalance, double-blinding, in-
complete outcome data, early stopping, and selective
outcome reporting. For individual studies, each criterion
was assigned a label of ‘yes,’ ‘unclear,’ or ‘no’ to estimate
the risk of bias. Two reviewers (Y.B. and W.S.Y.) per-
formed the quality assessment. Any discrepancies were
resolved by an intercessor (Z.R.Y.).
Data extraction
The two reviewers (Y.B. and W.S.Y.) independently ex-
tracted the following parameters from all included stud-
ies: basic information of the studies (authors, publication
year, duration of study, region in which the study was
performed, and randomization method), patient charac-
teristics (age, sex, number and size of tumors, number of
patients with hepatitis B and C virus infection, and liver
function), information on the intervention and compara-
tor evaluated in the study, and clinical outcomes (OS,
LR, CR, and complications). Most original data were ex-
tracted directly from the trials, but some data regarding
OS and LR were extracted from the published study
curves using the software Engauge Digitizer (version 4.1)
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soft Excel spreadsheet provided by Tierney et al. [36].
Outcome measures
In this meta-analysis, the primary outcome was OS.
The secondary outcomes were LR, CR, and the main
treatment-related complications that occurred during
the follow-up period.
Statistical analysis
The hazard ratio (HR) and 95% confidence interval (CI) of
the OS were calculated for each trial. Similarly, the risk ra-
tio (RR) and 95% CI of the LR and CR were determined.
Subgroup analyses were performed to explore import-
ant clinical differences between European and Asian tri-
als. Both random and fixed effects models were utilized
[37,38]. I2 and χ2 statistics of the HR were used to evaluateFigure 1 Study flow chart. ASCO, American Society of Clinical Oncology; CN
Literature Database; CQVIP, Chongqing VIP database; EMBASE, Excerpta Medicendpoint heterogeneity; studies with a P < 0.1 and I2 > 50%
were considered invalid, and the random effects model
was used. Otherwise, the data were pooled using the fixed
effects model. The significance of the pooled RR was
determined by the Z-test, and P < 0.05 was considered
statistically significant. All data obtained in this meta-
analysis were pooled and analyzed using the software
program Review Manager (version 5.0). Microsoft Excel
2010 was used to calculate the data. The guidelines de-




In total, 2,417 citations were identified in the search of
the electronic databases (Figure 1); 687 duplicates were
excluded, and 1,730 papers remained. We excluded 1,716KI, China National Knowledge Infrastructure; CBM, Chinese Biomedical
a dataBASE.
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initial screening, and 14 full-text articles were read for
further assessment. Two papers reported prospective
studies without additional details. One prospective non-
randomized study was excluded after obtaining infor-
mation via email from the author. However, we failed
to contact the corresponding author of another prospect-
ive nonrandomized study and thus excluded this paper be-
cause of its unclear study design. The remaining papers
were evaluated, and several more were excluded for the
reasons listed in Figure 1. Finally, eight RCTs met all
eligibility criteria and were included in this meta-analysis
[25-28,30,31,39,40]. Three RCTs were conducted in Italy
and were thus grouped as European studies [30,31,40],
four originated from Asia (Taiwan, n = 2 [25,26]; Japan,
n = 1 [27]; and China, n = 1 [28]), and one study from
Egypt was considered as an African study [39]. Although
the two studies from Taiwan were performed in the same
institution within 2 years, the corresponding author indi-
cated that the randomized patients in these two studies
did not overlap.Characteristics of included studies
In total, 1,130 patients were included among all selected
studies; 561 underwent RFA, and 569 underwent PEI.
The RFA and PEI groups contained 319 and 320 patients
with Child-Pugh class A liver function, respectively. The
average number of treatment sessions per tumor ranged
from 1.1 to 8.0. The male to female ratio was 1.97:1.00. The
mean tumor size ranged from 2.25 ± 0.45 to 2.8 ± 0.8 cm. A
total of 758 patients had a single lesion (RF, n = 381;
PEI, n = 377). The patients’ baseline characteristics are
presented in Table 1, and the details of the study end-
points are summarized in Table 2. Details on the quality
of each included study are presented in Table 3. A total
of 466 complications or adverse events occurred among
all patients in all studies (RFA, n = 247; PEI, n = 219)
(Table 4).Overall survival
Sensitivity analysis did not change the significance of the
results in the Asian studies. A fixed effects model was
used because of a lack of significant heterogeneity as
follows: Asia, I2 = 0%, P = 0.98; Europe, I2 = 0%, P = 0.90;
and total, I2 = 0%, P = 0.67 (Figure 2). Total effect of
comparison of RFA with PEI indicated that RFA was as-
sociated with better OS rates than PEI (HR, 0.67; 95%
CI 0.51 to 0.87; P < 0.01). In the Asian studies, RFA ex-
hibited better performance than PEI in terms of OS
(HR, 0.54; 95% CI: 0.37 to 0.80; P < 0.01). However, no
statistically significant difference was observed between
the two treatments in the European studies (HR, 0.82;
95% CI 0.56 to 1.20; P = 0.30).Local recurrence rate
Only five RCTs evaluated the LR because three did not
report relevant data [25-27,31,40]. Only one study con-
ducted in Europe reported the LR associated with a long-
term follow-up; thus, a subgroup analysis with HR could
not be performed. The RR was deemed to be an optimal
indicator to obtain additional information from these
original studies through comparison of RFA with PEI.
As shown in Figures 3 and 4, the pooled estimate of
the treatment indicated that RFA was associated with a
lower LR rate than was PEI at 1 year (RR, 0.44; 95% CI
0.22 to 0.85; P = 0.02) and 3 years (RR, 0.41; 95% CI 0.30
to 0.57; P < 0.01). The same condition was found in
the Asian studies at 1 year (RR, 0.44; 95% CI 0.20 to
0.95; P = 0.04) and 3 years (RR, 0.35; 95% CI 0.22 to
0.55; P < 0.01). In the European studies, however, no
significant differences were observed between the two
treatment groups at 1 year (RR, 0.35; 95% CI 0.05 to
2.59; P = 0.30) or 3 years (RR, 0.50; 95% CI 0.32 to
0.78; P < 0.01). The European data showed heterogen-
eity at 1 year (I2 = 68%, P = 0.08) and 3 years (I2 = 69%,
P = 0.07). Thus, the random effects models were derived.
Complete response
All eight studies reported the CR rate after RFA or PEI,
and six of them were suitable for pooling of the CR data
(both RFA and PEI exhibited a 100% CR rate in the two
remaining studies [27,31]).
The total pooled data showed that RFA was associated
with a better CR rate than PEI (RR, 1.15; 95% CI 1.05 to
1.27; P < 0.01) (Figure 5). A similar finding was observed in
the Asian studies (RR, 1.10; 95% CI 1.03 to 1.18; P < 0.01).
However, no significant differences were found between
the two treatment groups in the European studies (RR,
1.27; 95% CI 0.95 to 1.69; P = 0.11) or in the African study
(RR, 1.09; 95% CI 0.84 to 1.40; P = 0.52).
Complications
The main adverse events in the two treatment groups are
presented in Table 4. RFA was associated with more com-
plications than was PEI (n = 247 and 219, respectively).
The main differences between the two treatment groups
involved the incidence of skin burns, hydrothorax, liver
abscesses, hemothorax, and portal venous thrombosis.
Sensitivity analysis and publication bias
We performed a one-way sensitivity analysis to evaluate
the stability of the meta-analysis with respect to the Asian
studies. The sensitivity analysis did not change the signifi-
cance of the results in the Asian studies. A sensitivity ana-
lysis was not performed for the European trials because
only two studies were available [30,31]. A funnel plot indi-
cated that no significant publication bias was observed in
any of the studies (Figure 6).
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43 35/14 NA NA NA NA 2.4 ± 1.2 NA NA NA 11.2 ± 1.3 2
PEI
(49)
45 36/13 NA NA NA NA 2.3 ± 1.4 NA NA 11.2 ± 1.3
Azab,
2011
2005 to 2008 Egypt NA RFA
(30)
NA NA NA NA NA 16/17 NA NA 3–14 1.45 NA 3
PEI
(30)
NA NA NA NA NA 16/16 NA NA 7.68 NA
HBV, hepatitis B virus; HCV, hepatitis C virus; NA, not available; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; RNG, random number generator; Tx, treatment.





















Overall survival (%) Local recurrence (%)
1-year 2-year 3-year 4-year 5-year 1-year 2-year 3-year 4-year 5-year
Lencioni, 2003 RFA (52) 91.0 100.0 98.0 NA NA NA 2 4 21+ NA NA
PEI (50) 82.0 96.0 88.0 NA NA NA 17.0 38.0 59.0+ NA NA
Lin, 2004 RFA (52) 96.0 90.0 82.0 74.0 NA NA 12.0 18.0 18.0 NA NA
PEI (52) 88.0 85.0 61.0 50.0 NA NA 23.0 45.0 45.0 NA NA
Lin, 2005 RFA (62) 96.1 93.0 81.0 74.0 NA NA 10.0 14.0 14.0 NA NA
PEI (62) 88.1 88.0 66.0 51.0 NA NA 16.0 34.0 34.0 NA NA
Shiina, 2005 RFA (118) 100.0 96.0+ 91.0+ 81.0+ 74.0 NA 1.0+ 1.7+ 1.7+ 1.7+ NA
PEI (114) 100.0 93.0+ 81.0+ 66.0+ 57.0 NA 9.0+ 11.0+ 11.0+ 11.0+ NA
Brunello, 2008 RFA (70) 95.7 94.0+ 77.0+ 59.0+ 44.0+ NA NA NA NA NA NA
PEI (69) 65.6 87.0+ 74.0+ 56.0+ 42.0+ NA NA NA NA NA NA
Giorgio, 2011 RFA (128) 100.0 95.0 90.0 83.0 73.0 70.0 4.1 5.7 7.8 8.9 11.7
PEI (143) 100.0 95.0 83.0 78.0 70.0 68.0 5.2 6.7 9.4 11.5 12.8
Wang, 2011 RFA (49) 93.8 95.9 91.8 NA NA NA NA NA NA NA NA
PEI (49) 77.5 85.7 77.5 NA NA NA NA NA NA NA NA
Azab, 2011 RFA (30) 85.0 90.0 NA NA NA NA NA NA NA NA NA
PEI (30) 75.0 83.3 NA NA NA NA NA NA NA NA NA
NA, not available; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation.
+, data extracted from survival curves.
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The results from the Asian studies included in this
meta-analysis indicate that RFA is superior to PEI in
terms of OS, CR, and LR for patients with early-stage
nonsurgical HCC, which are consistent with previous
studies [24,41-47]. However, in the Asian studies included
in the present analysis, carcinomas near vessels were
treated only with PEI, and not by RFA, which can lead
to a bad prognosis. The resulting selection bias likely
influenced the apparent superiority of RFA, as evi-
denced by the lack of difference between the techniques
in the European studies. Although pooled data reported
by Weis et al. [45] indicated that RFA is superior to
PEI, their sub-analysis also showed no evidence for pro-
longed OS in European patients treated with RFATable 3 Risk of bias in the trials included in the present meta
Bias Lencioni, 2003 Lin, 2004 Lin, 2005 Shii
Sequence generation + + + +
Allocation concealment ? ? ? ?
Double-blinding − − − −
Incomplete outcome data − + − +
Selective outcome reporting − − − −
Other sources of bias − + + −
Early stopping ? − − −
Baseline imbalance − − − −
+, yes; −, no; ?, unclear.compared with PEI. The findings of this meta-analysis
indicate that there is insufficient evidence to conclude
that RFA is superior to PEI in patients with HCC tu-
mors ≤5 cm, consistent with the results of a systematic
review of the same trials [48]. Moreover, the effect of
both treatments is similar for patients with small HCC
tumors (<2 cm), as demonstrated by studies from Cho
et al. [14] and Germani et al. [44].
There are several potential factors affecting the dis-
crepancy between our overall findings on overall survival
and previous analyses. First, race may be a latent factor
that requires consideration and should not be ignored.
We failed to determine the impact of race because of the
shortage of required evidence. Second, the proportion of
patients with Child-Pugh class B cirrhosis was higher in-analysis
na, 2005 Brunello, 2008 Giorgio, 2011 Wang, 2011 Azab, 2011
+ + ? ?
+ + ? ?
− − − −
− − − −
+ − − −
− − − +
+ − − −
− − − −
Table 4 Major complications associated with
radiofrequency ablation and percutaneous ethanol
injection
Complication RFA (n = 247) PEI (n = 219)
Fever 58 52
Skin burns 6 0
Ascites 59 48
Jaundice 7 6
Liver abscess 0 2




Subcapsular hematoma 1 0
Portal venous thrombosis 5 9
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suggests that patients with Child-Pugh A liver function
treated with RFA have better outcomes, as indicated by
findings reported by Brunello et al. [30] and Giorgio
et al. [31]. Third, the limited number of smaller-scope
studies evaluating RFA gives rise to selection bias. Fourth,
the location of tumors can influence outcomes, as Bruix
and Sherman [23] stated that RFA can increase the risk of
severe complications in tumors located at high-risk sites.
Giorgio et al. [31] reported that tumors located in the sev-
enth and second liver segments are more suitable for
treatment by PEI than by RFA. Similarly, Ebara et al. [49]
found that 25% of lesions could not be treated by RFAFigure 2 Comparison of overall survival between radiofrequency abla
carcinoma (fixed effects model). CI, confidence interval; HR, hazard ratio;
SE, standard error.because of the unfavorable location of the tumor. The ex-
clusion criteria in two Asian studies in this meta-analysis
included tumors located within 5 to 10 mm of the liver
hila or the common bile duct [25-27], which are associated
with a risk of injury to the major bile duct following RFA
as reported by Brunello et al. [30] and Giorgio et al. [31].
Fifth, there is a lack of long-term data on patient survival;
the RCTs that evaluated the two percutaneous treatments
were small and had a short follow-up period. We found
that the OS in both groups became more similar as the
follow-up period lengthened, consistent with findings
reported by Shen et al. [43] and Bouza et al. [24]. This
is a critical factor that was not considered in previous
meta-analyses [41,42,47]. Sixth, only four of the included
trials reported the pathologic stage of the tumors, which
were unclear and may have induced a bias effect in our
study.
Similar results were found for LR and CR in the com-
parison between RFA and PEI. Both the total pooled data
and subgroup meta-analysis results of the Asian studies
implied that RFA is superior to PEI, consistent with the re-
sults of five other meta-analyses [24,41-44]. However,
these findings may also be unreliable for the reasons listed
above. The results of the European and African studies
indicated no differences in LR at 1 year, but a significant
discrepancy was present at 3 years [31]. Very similar re-
sults were obtained by Giorgio et al. [16]. Such findings
suggest that RFA provides local tumor control and more
CR than does PEI when the follow-up time is prolonged,
but additional studies are needed to more thoroughly
evaluate this.tion and percutaneous ethanol injection for hepatocellular
PEI, percutaneous ethanol injection; RFA, radiofrequency ablation;
Figure 3 Comparison of one-year local recurrence rates between radiofrequency ablation and percutaneous ethanol injection for
hepatocellular carcinoma (random effects model). CI, confidence interval; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation;
RR, risk ratio.
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among all patients in the RFA and PEI groups. However,
the total number of adverse events found in this meta-
analysis suggests that RFA may be associated with a higher
rate of adverse events, as reported by other studiesFigure 4 Comparison of three-year local recurrence rates between r
hepatocellular carcinoma (random effects model). CI, confidence interva
RR, risk ratio.[24,41-44]. This may be explained by the fact that the
diameter of the RFA electrode needle is larger than that
of the PEI needle, potentially leading to a higher risk of
complications such as hemothorax. On the other hand,
the temperature may quickly diffuse to a larger regionadiofrequency ablation and percutaneous ethanol injection for
l; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation;
Figure 5 Comparison of complete responses between radiofrequency ablation and percutaneous ethanol injection for hepatocellular
carcinoma (random effects model). CI, confidence interval; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; RR, risk ratio.
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is difficult to control and may readily lead to complica-
tions such as skin burns. Therefore, for small HCC, PEI
is associated with fewer complications and a broader
scope of treatment indications than RFA.Figure 6 Funnel plot for assessment of publication bias in included sLimitations of this study
We acknowledge that the conclusions of this meta-
analysis are limited by various factors. First, a small num-
ber of relevant studies were included. This may have led to
false-negative or false-positive conclusions. In particular,tudies. OR, odds ratio; SE, standard error.
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though the sensitivity analysis did not change the sig-
nificance of the results, the outcomes of the European
trials are still weakened. Second, only five studies pre-
sented survival curves or HR-related data. Third, some
trials did not involve a randomization procedure, which
may have affected the accuracy of the outcomes [22,36].
Third, none of the trials blinded the treatment providers
because of the nature of the interventional operation. For-
tunately, the primary outcome was not affected by blind-
ing because the studies reported the mortality rates [50].
Fourth, however, the secondary outcomes may have been
affected by performance and detection bias, which may
have resulted in imprecise findings of this meta-analysis.
Fifth, the baseline characteristics of the included studies,
such as tumor size, number of lesions, and different tech-
nical procedures, may have limited the accuracy of the
pooled data. Sixth, some data were directly extracted from
the OS and LR curves because of the lack of original data.
Although we did our best to extract and calculate the
necessary data using the software Engauge Digitizer [36],
some error is inevitable. Nevertheless, the Cochrane
Collaborative Group recommends that not all data need
to be perfectly accurate when some patient data are
lacking [34]. Seventh, none of the trials were powerful
enough to identify differences in OS because of small
sample sizes and short follow-up durations. Finally, het-
erogeneity was found in the studies included in this
meta-analysis. This may be explained by the fact that more
patients had hepatitis B infection, higher α-fetoprotein
levels, and the inclusion of HCC nodules of >5 cm in the
study by Lencioni et al. [40]. However, technologic dispar-
ity among the studies may the most important reason for
the observed heterogeneity.
A number of credible techniques were used to reduce
potential bias, including an extensive search of the litera-
ture, strict guidelines regarding duplicate data extraction,
the use of clear criteria, and the use of a random effects
model for effect estimation and contacting the correspond-
ing authors by email. In spite of all the above-described
limitations, this study provides the most thorough com-
parison of RFA and PEI.Conclusion
The findings of the present meta-analysis indicate that
there is no reliable evidence to support the idea that RFA
is superior to PEI for patients, especially in Europe, with
cirrhotic HCC. Additional large-scale RCTs with less se-
lection bias are still needed.Competing interests
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